Aligos Therapeutics, Inc. (ALGS) Form 10-Q Quarterly Reports
Aligos Therapeutics, Inc. (ALGS) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ALGS
CIK: 1799448
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Ernst & Young LLP
Auditor SinceSince 12/31/2019 12:00:00 AM
Lead Engagement PartnerMarcus Lindner
Audit LocationSan Francisco, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-09-15 | 2026-09-10 | 8-K | 0001193125-26-391880 | View SEC Doc Filr Page |
| S-8 | 2026-08-06 | — | S-8 | 0001193125-26-337937 | View SEC Doc Filr Page |
| 10-Q | 2026-08-06 | 2026-06-30 | 10-Q | 0001193125-26-336851 | View SEC Doc Filr Page |
| 8-K | 2026-08-06 | 2026-08-06 | FORM 8-K | 0001171843-26-005294 | View SEC Doc Filr Page |
| 4 | 2026-06-29 | 2026-06-25 | 4 Filing | 0001610717-26-000305 | View SEC Doc Filr Page |
| 4 | 2026-06-29 | 2026-06-25 | 4 Filing | 0001610717-26-000304 | View SEC Doc Filr Page |
| 4 | 2026-06-29 | 2026-06-25 | 4 Filing | 0001610717-26-000303 | View SEC Doc Filr Page |
| 4 | 2026-06-29 | 2026-06-25 | 4 Filing | 0001610717-26-000302 | View SEC Doc Filr Page |
| 4 | 2026-06-29 | 2026-06-25 | 4 Filing | 0001610717-26-000301 | View SEC Doc Filr Page |
| 4 | 2026-06-29 | 2026-06-25 | 4 Filing | 0001610717-26-000300 | View SEC Doc Filr Page |
| 8-K | 2026-06-26 | 2026-06-25 | 8-K | 0001193125-26-285426 | View SEC Doc Filr Page |
| SCHEDULE 13D | 2026-06-24 | — | SCHEDULE 13D Filing | 0001193125-26-281134 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-05-15 | — | SCHEDULE 13G Filing | 0001193125-26-226938 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0000919574-26-003231 | View SEC Doc Filr Page |
| 10-Q | 2026-05-07 | 2026-03-31 | 10-Q | 0001193125-26-212001 | View SEC Doc Filr Page |
| 8-K | 2026-05-07 | 2026-05-07 | FORM 8-K | 0001171843-26-003156 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-29 | — | DEFA14A | 0001193125-26-191940 | View SEC Doc Filr Page |
| ARS | 2026-04-29 | 2025-12-31 | ARS | 0001193125-26-191897 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-29 | 2026-06-25 | DEF 14A | 0001193125-26-191843 | View SEC Doc Filr Page |
| 8-K | 2026-04-21 | 2026-04-16 | 8-K | 0001193125-26-166987 | View SEC Doc Filr Page |
| 8-K | 2026-04-14 | 2026-04-14 | 8-K | 0001193125-26-154927 | View SEC Doc Filr Page |
| 4 | 2026-03-11 | 2026-03-09 | 4 Filing | 0001610717-26-000095 | View SEC Doc Filr Page |
| 4 | 2026-03-11 | 2026-03-09 | 4 Filing | 0001610717-26-000094 | View SEC Doc Filr Page |
| 4 | 2026-03-11 | 2026-03-09 | 4 Filing | 0001610717-26-000093 | View SEC Doc Filr Page |
| 4 | 2026-03-11 | 2026-03-09 | 4 Filing | 0001610717-26-000092 | View SEC Doc Filr Page |